Climb Bio, INC. (CLYM) — DEF 14A Filings
All DEF 14A filings from Climb Bio, INC.. Browse 1 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (1)
-
Climb Bio Files Definitive Proxy Statement
— Apr 25, 2025 Risk: low
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed a definitive proxy statement (DEF 14A) on April 25, 2025, for its fiscal year ending December 31, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX